Wedbush Increases Epizyme (EPZM) Price Target to $25.00

Epizyme (NASDAQ:EPZM) had its price target hoisted by analysts at Wedbush from $20.00 to $25.00 in a note issued to investors on Friday. Wedbush’s price objective suggests a potential upside of 47.06% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on the company. Jefferies Group reaffirmed a “buy” rating and set a $25.00 target price on shares of Epizyme in a research report on Wednesday, January 24th. BidaskClub raised Epizyme from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 24th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Roth Capital started coverage on Epizyme in a research report on Thursday, February 1st. They set a “buy” rating and a $24.00 target price for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $27.00 target price on shares of Epizyme in a research report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $22.92.

Shares of Epizyme opened at $17.00 on Friday, MarketBeat Ratings reports. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -7.80 and a beta of 2.00. Epizyme has a 12-month low of $9.30 and a 12-month high of $21.40.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. During the same period in the prior year, the firm posted ($0.56) EPS. equities analysts forecast that Epizyme will post -2.24 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. TIAA CREF Investment Management LLC boosted its position in shares of Epizyme by 2.6% in the fourth quarter. TIAA CREF Investment Management LLC now owns 112,844 shares of the biopharmaceutical company’s stock valued at $1,416,000 after acquiring an additional 2,832 shares during the period. Northern Trust Corp boosted its position in shares of Epizyme by 0.6% in the first quarter. Northern Trust Corp now owns 580,898 shares of the biopharmaceutical company’s stock valued at $10,311,000 after acquiring an additional 3,538 shares during the period. Rhumbline Advisers boosted its position in shares of Epizyme by 9.4% in the first quarter. Rhumbline Advisers now owns 48,210 shares of the biopharmaceutical company’s stock valued at $856,000 after acquiring an additional 4,130 shares during the period. Bailard Inc. boosted its position in shares of Epizyme by 25.0% in the first quarter. Bailard Inc. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $444,000 after acquiring an additional 5,000 shares during the period. Finally, American International Group Inc. boosted its position in shares of Epizyme by 19.3% in the fourth quarter. American International Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 5,334 shares during the period. 86.34% of the stock is owned by institutional investors.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply